Our initial focus is asthma where we monitor changes in fractional exhaled nitric oxide (feno) to determine adherence, efficacy of medication, and risk of attack. Mybiometry’s products are currently in development and have not yet been cleared by the fda. Mybiometry’s vision is to empower people with asthma and copd to live healthier lives by providing them with proactive and actionable data to prevent attacks at home.
Baby Breezy OnlyFans Account - officialbabybreezy
Our initial focus is asthma.
About mybiometry mybiometry is a health technology company dedicated to empowering patients and health care providers through advanced biometric monitoring solutions
This successful funding round marks a pivotal step for mybiometry in addressing a significant unmet need in chronic respiratory care Asthma and copd affect millions, with a substantial number of patients experiencing exacerbations that drive up healthcare costs and strain resources. Welcome to the cloud biometrycreate new company sign up The aim is to offer personalized, predictive risk models for each patient, so patients can take action to ultimately improve asthma control
While their initial focus is asthma, the company hopes to expand to support other chronic health conditions in the future Learn more about mybiometry here. Headquartered in massachusetts, with operations in indiana, mybiometry is at the forefront of transforming respiratory care for chronic disease patients
